GENE ONLINE|News &
Opinion
Blog

2021-07-16| ChinaIPO

China’s Brii Bio Raises $319 million in the Hong Kong IPO

by Tyler Chen
Share To

China’s Brii Biosciences has raised $319 million in the initial public offering (IPO) in HKEX. The company announced that the proceeds would be used to support the development of its infectious diseases pipeline, including HBV, HIV, and COVID-19 therapies.

The firm released around 111 million shares on July 13th at HK$22.25 per share, and the cornerstone investors have agreed to acquire 47.52% of them.

“Listing on the Hong Kong Stock Exchange marks an important milestone for our company,” Brii Bio’s CEO Zhi Hong pointed out, “By leveraging our remarkable senior management as well as our experience of conducting multi-regional clinical trials, we will continue to expand our pipeline through our in-house R&D efforts, and in-licenses or collaborations on appropriate drug candidates.”

Brii Bio’s main focus is to deliver innovative solutions to treating infectious diseases and central nervous system (CNS) diseases. Their star pipeline included treatments for HBV, HIV, multidrug-resistant (MDR), extensive drug-resistant (XDR) gram-negative infections, and COVID-19.

Currently, the COVID-19 antibodies BRII-196 and BRII-198 are the most advanced in clinical trials. Both of them have entered phase 3 clinical trials. On the other hand, HBV therapies BRII-179 (immuno-therapy), BRII-835 (siRNA), and the combination therapies come next, entering Phase 2 clinical trials while HIV treatments are in Phase 1 trials.

As for CNS therapies, BRII-296 is tested for two indications: a Phase 1 clinical trial targeting postpartum depression (PPD) and the other in the preclinical stage addressing major depressive disorder (MDD).

On March 23rd, Brii Bio finished the Series C financing, scoring $155 million to boost its current pipeline.

Related Article: Chinese Oncology Drugmaker to Raise over 600 Million in Hong Kong IPO

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Investigate the Current Status of Rivaroxaban Generic Drug Application in China
2023-03-01
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
WuXi Biologics, Toregem BioPharma To Develop Tooth-Regenerating Antibody
2022-10-14
LATEST
Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
2023-03-28
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
2023-03-28
Vertex and CRISPR Collaborate Again with $330 Million Diabetes Gene Editing Deal
2023-03-28
Amway Applauded by Frost & Sullivan for Capitalizing on Innovative Competitive Strategies to Drive Differentiation in Its Home Water Treatment Solution in APAC
2023-03-28
BJ Bioscience Announces Clinical Collaboration with MSD to Evaluate BJ-001 in Combination with KEYTRUDA® (pembrolizumab)
2023-03-27
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Scroll to Top